BioCryst Pharmaceuticals is involved in litigation regarding its hereditary angioedema (HAE) drug, Orladeyo (berotralstat) [1]. The company has sued generics manufacturers alleging patent infringement [1].
What is Orladeyo (berotralstat) and why is it patented?
Orladeyo is a once-daily, oral therapy approved for the prophylactic treatment of HAE in patients 12 years of age and older [2]. It works by targeting the plasma kallikrein enzyme, which plays a role in HAE attacks [2]. BioCryst has patents covering the composition of matter, methods of use, and manufacturing processes for berotralstat [1]. These patents are crucial for protecting the company's investment in research, development, and commercialization of the drug [1].
Who is BioCryst suing over Orladeyo?
BioCryst has filed patent infringement lawsuits against several generic drug companies that have sought to market their own versions of berotralstat [1]. These actions are typical when a brand-name drug's patents are nearing expiration or when generic companies file abbreviated new drug applications (ANDAs) [1].
When might generic versions of Orladeyo become available?
The timing of generic entry for Orladeyo depends on the outcomes of the patent litigation and the expiration of the relevant patents [1]. While the query mentions March 2025, patent exclusivity and the legal challenges surrounding it can extend beyond initial expiration dates [1]. Information on specific patent expiry dates and potential generic launch timelines can be found on resources like DrugPatentWatch.com [1].
What are the implications of these lawsuits for BioCryst and patients?
These lawsuits are an effort by BioCryst to defend its market exclusivity for Orladeyo, which is important for recouping its development costs and funding future innovation [1]. For patients, the outcome of these legal battles will influence the availability and price of generic HAE treatments [3]. If BioCryst is successful in enforcing its patents, the launch of lower-cost generic alternatives may be delayed [3]. Conversely, if generic manufacturers prevail, it could lead to more affordable treatment options for individuals with HAE [3].
How does BioCryst's patent litigation compare to other drug companies?
Patent litigation is a common aspect of the pharmaceutical industry. Drug manufacturers routinely defend their patents against challenges from generic companies [1]. The specifics of each case, including the patents in question and the alleged infringement, vary widely [1].
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.orladeyo.com/
[3] Information gathered from general knowledge of pharmaceutical patent law and market dynamics.